Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

Josep M. Llovet; Gregory J. Gores

doi:10.1093/jnci/djn342

Related publications

Article2020

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, Myron Schwartz, Tim Meyer, Peter R. Galle, Riccardo Lencioni, Tim F. Greten, Masatoshi Kudo, Sumithra J. Mandrekar, Andrew X. Zhu, Richard S. Finn, Lewis R. Roberts

Hepatology

Article2008

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

Josep M. Llovet, Adrian M. Di Bisceglie, Jordi Bruix, Barnett S. Kramer, Riccardo Lencioni, Andrew X. Zhu, Morris Sherman, Myron Schwartz, Michael T. Lotze, Jayant A. Talwalkar, Gregory J. Gores

JNCI Journal of the National Cancer Institute

Letter2022

Reply: Composite endpoints in clinical trials - simplicity or perfection?

Hironori Hara, Yoshinobu Onuma, Patrick W. Serruys

EuroIntervention

Article2003

Hepatocellular carcinoma: a clinical update.

Fernando Pons-Renedo, Josep M. Llovet

PubMed

Article2009

815 SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA. FEASIBILITY AND SAFETY OUTSIDE RESEARCH TRIALS

María Reig, Alejandro Forner, Jordi Rimola, Carlos Rodríguez de Lope, Carmen Ayuso, Josep M. Llovet, Jordi Bruix

Journal of Hepatology